InsiderTrades

Form 4 for TXMD TherapeuticsMD, Inc.

Accepted 2022-12-09 00:00:00 ET · period of report 2022-12-06 · accession 0001209191-22-060586 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-12-09 2022-12-06 TXMD Glickman Mark A Co-CEO S - Sale+OE $4.92 -440 1,294 -25% -$2,165
D 2022-12-09 2022-12-06 TXMD Glickman Mark A Co-CEO M - OptEx $0.00 +1,734 1,734 New $0
D 2022-12-09 2022-12-06 TXMD Glickman Mark A Co-CEO M - OptEx $0.00 -1,734 3,466 -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-12-06 S D 440 $4.92 1,294 D — —
2 Common Common Stock 2022-12-06 M A 1,734 $0.00 1,734 D — — (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).
3 Derivative Restricted Stock Units 2022-12-06 M D 1,734 $0.00 3,466 D $0.00 · — to — 1,734 Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs). (F3) The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.